Novel Anti-Angiogenic and Anti-Tumour Activities of the N-Terminal Domain of NOEY2 via Binding to VEGFR-2 in Ovarian Cancer |
Rho, Seung Bae
(Division of Translational Science, Research Institute, National Cancer Center)
Lee, Keun Woo (Department of Biochemistry, Division of Applied Life Science, Environmental Biotechnology National Core Research Center, Gyeongsang National University) Lee, Seung-Hoon (Department of Life Science, Yong In University) Byun, Hyun Jung (BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University) Kim, Boh-Ram (Division of Translational Science, Research Institute, National Cancer Center) Lee, Chang Hoon (BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University) |
1 | Nishimoto, A., Yu, Y., Lu, Z., Mao, X., Ren, Z., Watowich, S. S., Mills, G. B., Liao, W. S., Chen, X., Bast, R. C., Jr. and Luo, R. Z. (2005) A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res. 65, 6701-6710. DOI |
2 | Luo, R. Z., Fang, X., Marquez, R., Liu, S. Y., Mills, G. B., Liao, W. S., Yu, Y. and Bast, R. C. (2003) ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 22, 2897-2909. DOI |
3 | Byrne, A. M., Bouchier-Hayes, D. J. and Harmey, J. H. (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell. Mol. Med. 9, 777-794. DOI |
4 | Zhong, C., Shu, M., Ye, J., Wang, X., Chen, X., Liu, Z., Zhao, W., Zhao, B., Zheng, Z., Yin, Z., Gao, M., Zhao, H., Wang, K. and Zhao, S. (2019) Oncogenic Ras is downregulated by ARHI and induces autophagy by Ras/AKT/mTOR pathway in glioblastoma. BMC Cancer 19, 441. DOI |
5 | Meadows, K. N., Bryant, P. and Pumiglia, K. (2001) Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J. Biol. Chem. 276, 49289-49298. DOI |
6 | Rho, S. B., Kim, M. J., Lee, J. S., Seol, W., Motegi, H., Kim, S. and Shiba, K. (1999) Genetic dissection of protein-protein interactions in multi-tRNA synthetase complex. Proc. Natl. Acad. Sci. U.S.A. 96, 4488-4493. DOI |
7 | Spannuth, W. A., Nick, A. M., Jennings, N. B., Armaiz-Pena, G. N., Mangala, L. S., Danes, C. G., Lin, Y. G., Merritt, W. M., Thaker, P. H., Kamat, A. A., Han, L. Y., Tonra, J. R., Coleman, R. L., Ellis, L. M. and Sood, A. K. (2009) Functional significance of VEGFR-2 on ovarian cancer cells. Int. J. Cancer 124, 1045-1053. DOI |
8 | Rho, S. B., Lee, S. H., Byun, H. J., Kim, B. R. and Lee, C. H. (2020) IRF-1 inhibits angiogenic activity of HPV16 E6 oncoprotein in cervical cancer. Int. J. Mol. Sci. 21, 7622. DOI |
9 | Risau, W. (1997) Mechanisms of angiogenesis. Nature 386, 671-674. DOI |
10 | Rho, S. B., Song, Y. J., Lim, M. C., Lee, S. H., Kim, B. R. and Park, S. Y. (2012) Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell. Signal. 24, 131-139. DOI |
11 | Shen, W., Li, H., Liu, L. and Cheng, J. (2017) Expression levels of PTEN, HIF-1alpha, and VEGF as prognostic factors in ovarian cancer. Eur. Rev. Med. Pharmacol. Sci. 21, 2596-2603. |
12 | Shi, R., Liao, C. and Zhang, Q. (2021) Hypoxia-driven effects in cancer: characterization, mechanisms, and therapeutic implications. Cells 10, 678. DOI |
13 | Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209-249. DOI |
14 | Sutton, M. N., Lu, Z., Li, Y. C., Zhou, Y., Huang, T., Reger, A. S., Hurwitz, A. M., Palzkill, T., Logsdon, C., Liang, X., Gray, J. W., Nan, X., Hancock, J., Wahl, G. M. and Bast, R. C., Jr. (2019) DIRAS3 (ARHI) blocks RAS/MAPK signaling by binding directly to RAS and disrupting RAS clusters. Cell Rep. 29, 3448-3459.e6. DOI |
15 | Tuninetti, V., Di Napoli, M., Ghisoni, E., Maggiorotto, F., Robella, M., Scotto, G., Giannone, G., Turinetto, M., Siatis, D., Ponzone, R., Vaira, M., De Simone, M., Scaffa, C., Pignata, S., Greggi, S., Di Maio, M. and Valabrega, G. (2020) cytoreductive surgery for heavily pre-treated, platinum-resistant epithelial ovarian carcinoma: a two-center retrospective experience. Cancers (Basel) 12, 2239. DOI |
16 | Bamberger, E. S. and Perrett, C. W. (2002) Angiogenesis in epithelian ovarian cancer. Mol. Pathol. 55, 348-359. DOI |
17 | Ferrara, N. (2002) VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795-803. DOI |
18 | Bao, J. J., Le, X. F., Wang, R. Y., Yuan, J., Wang, L., Atkinson, E. N., LaPushin, R., Andreeff, M., Fang, B., Yu, Y. and Bast, R. C., Jr. (2002) Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspaseindependent calpain-dependent pathway. Cancer Res. 62, 7264-7272. |
19 | Birner, P., Schindl, M., Obermair, A., Breitenecker, G. and Oberhuber, G. (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7, 1661-1668. |
20 | Conteduca, V., Kopf, B., Burgio, S. L., Bianchi, E., Amadori, D. and De Giorgi, U. (2014) The emerging role of anti-angiogenic therapy in ovarian cancer (review). Int. J. Oncol. 44, 1417-1424. DOI |
21 | Gasper, R., Sot, B. and Wittinghofer, A. (2010) GTPase activity of DiRas proteins is stimulated by Rap1GAP proteins. Small GTPases 1, 133-141. DOI |
22 | Guo, B. Q. and Lu, W. Q. (2018) The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer. Oncotarget 9, 30552-30560. DOI |
23 | Hicklin, D. J. and Ellis, L. M. (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011-1027. DOI |
24 | Zagzag, D., Zhong, H., Scalzitti, J. M., Laughner, E., Simons, J. W. and Semenza, G. L. (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88, 2606-2618. DOI |
25 | Horikawa, N., Abiko, K., Matsumura, N., Hamanishi, J., Baba, T., Yamaguchi, K., Yoshioka, Y., Koshiyama, M. and Konishi, I. (2017) Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin. Cancer Res. 23, 587-599. DOI |
26 | Wang, X., Bove, A. M., Simone, G. and Ma, B. (2020) Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front. Cell Dev. Biol. 8, 599281. DOI |
27 | Wigerup, C., Pahlman, S. and Bexell, D. (2016) Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol. Ther. 164, 152-169. DOI |
28 | Yu, L., Kim, H. J., Park, M. K., Byun, H. J., Kim, E. J., Kim, B., Nguyen, M. T., Kim, J. H., Kang, G. J., Lee, H., Kim, S. Y., Rho, S. B. and Lee, C. H. (2021) Ethacrynic acid, a loop diuretic, suppresses epithelial-mesenchymal transition of A549 lung cancer cells via blocking of NDP-induced WNT signaling. Biochem. Pharmacol. 183, 114339. DOI |
29 | Yu, Y., Xu, F., Peng, H., Fang, X., Zhao, S., Li, Y., Cuevas, B., Kuo, W. L., Gray, J. W., Siciliano, M., Mills, G. B. and Bast, R. C., Jr. (1999) NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl. Acad. Sci. U.S.A. 96, 214-219. DOI |
30 | Lu, Z., Luo, R. Z., Lu, Y., Zhang, X., Yu, Q., Khare, S., Kondo, S., Kondo, Y., Yu, Y., Mills, G. B., Liao, W. S. and Bast, R. C., Jr. (2008) The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J. Clin. Invest. 118, 3917-3929. DOI |
31 | Maharjan, S., Park, B. K., Lee, S. I., Lim, Y., Lee, K., Lee, Y. and Kwon, H. J. (2019) Gomisin G suppresses the growth of colon cancer cells by attenuation of AKT phosphorylation and arrest of cell cycle progression. Biomol. Ther. (Seoul) 27, 210-215. DOI |
32 | Majmundar, A. J., Wong, W. J. and Simon, M. C. (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294-309. DOI |
33 | Mao, W., Peters, H. L., Sutton, M. N., Orozco, A. F., Pang, L., Yang, H., Lu, Z. and Bast, R. C., Jr. (2019) The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. Cancer 125, 1267-1280. DOI |
34 | Masoud, G. N. and Li, W. (2015) HIF-1alpha pathway: role, regulation and intervention for cancer therapy. Acta Pharm. Sin. B 5, 378-389. DOI |
35 | Dauber-Osguthorpe, P., Roberts, V. A., Osguthorpe, D. J., Wolff, J., Genest, M. and Hagler, A. T. (1988) Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductasetrimethoprim, a drug-receptor system. Proteins 4, 31-47. DOI |
36 | Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H. and Shu, Y. (2019) Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer 18, 157. DOI |
37 | Kang, S., Dong, S. M., Kim, B. R., Park, M. S., Trink, B., Byun, H. J. and Rho, S. B. (2012) Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis 17, 989-997. DOI |
38 | Li, T., Kang, G., Wang, T. and Huang, H. (2018) Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol. Lett. 16, 687-702. |
39 | Kim, B. R., Seo, S. H., Park, M. S., Lee, S. H., Kwon, Y. and Rho, S. B. (2015) sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1alpha signaling pathways. Oncotarget 6, 31830-31843. DOI |
40 | Lheureux, S., Braunstein, M. and Oza, A. M. (2019) Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J. Clin. 69, 280-304. |
41 | Lu, Z., Yang, H., Sutton, M. N., Yang, M., Clarke, C. H., Liao, W. S. and Bast, R. C., Jr. (2014) ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death Differ. 21, 1275-1289. DOI |
42 | Lugano, R., Ramachandran, M. and Dimberg, A. (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 77, 1745-1770. DOI |
43 | Plate, K. H., Breier, G., Weich, H. A. and Risau, W. (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848. DOI |
44 | Rankin, E. B. and Giaccia, A. J. (2008) The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 15, 678-685. DOI |
45 | Rho, S. B., Lee, K. H., Kim, J. W., Shiba, K., Jo, Y. J. and Kim, S. (1996) Interaction between human tRNA synthetases involves repeated sequence elements. Proc. Natl. Acad. Sci. U.S.A. 93, 10128-10133. DOI |